Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.

CATX | US

Overview

Corporate Details

ISIN(s):
US46489V1044 (+1 more)
LEI:
Country:
United States of America
Address:
2401 ELLIOTT AVENUE, 98121 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company pioneering advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its proprietary technology platform uses a revolutionary lead-212 (Pb-212) based approach, conjugating radioisotopes to high-affinity targeting peptides. This theranostic method allows physicians to first image tumors to confirm targets and then deliver potent, short-range alpha radiation directly to cancer cells, aiming to maximize efficacy while minimizing damage to surrounding healthy tissue. The company's clinical pipeline is focused on oncology, with programs targeting melanoma, neuroendocrine tumors, and other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Perspective Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perspective Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perspective Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America GILD

Talk to a Data Expert

Have a question? We'll get back to you promptly.